Akebia Therapeutics, Inc. (AKBA) Financial Statements (2025 and earlier)

Company Profile

Business Address 245 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:51,87042,92590,466149,800268,690147,694
Cash and cash equivalent51,87042,92590,466149,800228,698147,449
Short-term investments      245
Other undisclosed cash, cash equivalents, and short-term investments     39,992 
Receivables34,36839,29040,28450,87526,85338,864
Inventory, net of allowances, customer advances and progress billings16,24315,69121,56838,19561,017116,349
Inventory16,24315,69121,56838,19561,017116,349
Other current assets7,3215,754    
Other undisclosed current assets 4,02914,48932,86433,14014,8776,626
Total current assets:113,831118,149185,182272,010371,437309,533
Noncurrent Assets
Operating lease, right-of-use asset8,21812,41629,15833,85226,87629,038
Property, plant and equipment2,2003,6295,2146,7548,62210,380
Intangible assets, net (including goodwill)59,04495,086131,128163,180199,223346,265
Goodwill59,04459,04459,04455,05355,05355,053
Intangible assets, net (excluding goodwill)  36,04272,084108,127144,170291,212
Other noncurrent assets37,37712,4235,37249,75437,98175,985
Total noncurrent assets:106,839123,554170,872253,540272,702461,668
TOTAL ASSETS:220,670241,703356,054525,550644,139771,201
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities78,64082,37093,798138,044171,932168,288
Accounts payable15,18014,63518,02133,58841,30839,217
Accrued liabilities63,46067,73575,777104,456130,624129,071
Deferred revenue  3,73820,90615,21439,830
Debt  17,50032,00097,543  
Other undisclosed current liabilities2,274     
Total current liabilities:80,91499,870129,536256,493187,146208,118
Noncurrent Liabilities
Long-term debt and lease obligation38,69317,18334,07833,703120,999103,333
Long-term debt, excluding current maturities38,69317,18334,078 96,37875,805
Liabilities, other than long-term debt13,47261,128128,966103,99985,95663,343
Deferred revenue  43,29643,29621,47425,34533,120
Customer refund liability   40,992   
Other liabilities4,7498,88515,71782,52560,61130,223
Operating lease, liability3,5478,94728,96133,70324,62127,528
Derivative instruments and hedges, liabilities5,176     
Other undisclosed noncurrent liabilities136,77694,10658,24454,8992,4201,650
Total noncurrent liabilities:188,941172,417221,288192,601209,375168,326
Total liabilities:269,855272,287350,824449,094396,521376,444
Equity
Equity, attributable to parent(49,185)(30,584)5,23076,456247,618394,757
Common stock222111
Additional paid in capital1,629,1671,578,3581,562,2471,536,8001,425,1151,188,810
Accumulated other comprehensive income666613 
Accumulated deficit(1,678,360)(1,608,950)(1,557,025)(1,460,351)(1,177,511)(794,054)
Total equity:(49,185)(30,584)5,23076,456247,618394,757
TOTAL LIABILITIES AND EQUITY:220,670241,703356,054525,550644,139771,201

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues160,180194,623292,484213,578295,307335,001
Cost of revenue(63,177)(74,149)(85,568)(153,394)(295,908)(145,336)
Cost of product and service sold(63,177)(74,149)(85,568)(153,394)(180,381)(108,935)
Gross profit:97,003120,474206,91660,184(601)189,665
Operating expenses(147,475)(166,730)(287,695)(325,502)(375,841)(475,953)
Operating income (loss):(50,472)(46,256)(80,779)(265,318)(376,442)(286,288)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
948873,1462,4141,856(794)
Interest and debt expense (517) (906)   
Income (loss) from continuing operations before equity method investments, income taxes:(50,895)(45,369)(78,539)(262,904)(374,586)(287,082)
Other undisclosed income (loss) from continuing operations before income taxes(18,515)(6,556)(15,687)(19,936)(8,871)792
Loss from continuing operations before income taxes:(69,410)(51,925)(94,226)(282,840)(383,457)(286,290)
Income tax benefit      6,631
Loss from continuing operations:(69,410)(51,925)(94,226)(282,840)(383,457)(279,659)
Loss before gain (loss) on sale of properties:(282,840)(383,457)(279,659)
Net loss available to common stockholders, diluted:(69,410)(51,925)(94,226)(282,840)(383,457)(279,659)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(69,410)(51,925)(94,226)(282,840)(383,457)(279,659)
Comprehensive loss:(69,410)(51,925)(94,226)(282,840)(383,457)(279,659)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (7)13261
Comprehensive loss, net of tax, attributable to parent:(69,410)(51,925)(94,226)(282,847)(383,444)(279,398)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: